Clinical study on the effect of alprostadil on pulmonary function during pediatric liver transplantation

Clinical study on lung protection of alprostadil in pediatric liver transplantation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058292

Enrollment

Unknown

Registered

2022-04-04

Start date

2022-04-06

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group C:In the new liver stage, alprostadil 0.5 ng·kg-1·min-1 was given to the end of the operation

Group K:0.5 ng·kg-1·min-1 of alprostadil was given at the beginning of the operation until the end of the operation

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. First liver transplantation; 2. No severe arrhythmias, heart function grade II or III, and liver function Child-Pugh grade B or C; 3. Obtain the consent of the child's guardian and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined multi-organ transplantation; 2. Severe respiratory diseases.

Design outcomes

Primary

Measure	Time frame
CC16 protein concentration;	—

Secondary

Measure	Time frame
blood gas analysis;	—

Countries

China

Contacts

Public ContactLan Yuyan

Guangxi Medical University

119707472@qq.com+86 13878804622

Outcome results